Therapeutic applications of toll-like receptors (TLRs) agonists in AML

• Ye Peng ^[2] ; Yanzhong Wang ^[1] ; Manling Wang ^[2] ; Jianping Lan ^[2] ; Yirui Chen ^[2]
  1. [1] Zhejiang University

     Zhejiang University

     China

     
  2. [2] Cancer Center, Department of Hematology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, 58 Shangtang Road, Hangzhou, 310014, Zhejiang, People’s Republic of China
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 12 (December), 2022, págs. 2319-2329
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Acute myeloid leukemia (AML) is an aggressive type of blood cancer affecting bone marrow (BM). In AML, hematopoietic precursors are arrested in the early stages of development and are defined as the presence of ≥ 20% blasts (leukemia cells) in the BM. Toll-like receptors (TLR) are major groups of pattern recognition receptors expressed by almost all innate immune cells that enable them to detect a wide range of pathogen-associated molecular patterns and damage-associated molecular patterns to prime immune responses toward adaptive immunity. Because TLRs are commonly expressed on transformed immune system cells (ranging from blasts to memory cells), they can be a potential option for developing efficient clinical alternatives in hematologic tumors. This is because several in vitro and in vivo investigations have demonstrated that TLR signaling increased the immunogenicity of AML cells, making them more vulnerable to T cell-mediated invasion. This study aimed to review the current knowledge in this field and provide some insight into the therapeutic potentials of TLRs in AML.